ACAD Q1 2023 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

ACADACADIA Pharmaceuticals Inc.

$4B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$118M+2.6% YoY

Gross Profit

$117M98.6% margin

Operating Income

-$54M-45.2% margin

Net Income

-$43M-36.3% margin

EPS (Diluted)

$-0.27

QoQ Revenue Growth

-13.2%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$655M

Total Liabilities

$281M

Stockholders' Equity

$374M

Cash & Equivalents

$291M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$118M	$115M	+2.6%
Gross Profit	$117M	$113M	+3.8%
Operating Income	-$54M	-$113M	+52.6%
Net Income	-$43M	-$113M	+61.9%